Free-To-Play Fantasy MMORPG Mabinogi Celebrates Its 14th Anniversary On March 27!
Today, leading game publisher Nexon announced its venerable free-to-play fantasy MMORPG Mabinogi will be celebrating its 14th anniversary on March 27. Players will be able to engage in celebratory bonuses and activities for the game’s anniversary through April 14. As part of continuing quality of life improvements, Mabinogi will also be merging servers on April 14, so that global players can continue to embark on mystical adventures together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005803/en/
Mabinogi (Graphic: Business Wire)
The 14th anniversary celebration will include an abundance of updates from equipment repair cost reduction to 20% of the original price to Crom Bás dungeon polishing such as increased drop rate and overall dungeon length reduction. Additionally, the celebration brings a range of prizes, new missions and quests, starting on March 17, including:
- 14th Anniversary Night Bazaar - Meet Dero the Eventsman near Festia’s Main Gate and register your main character to participate in this guide quest, receive prizes, and play mini-games. Plus, all characters will be able to receive a 14th Anniversary Check design when issuing a check from the Tir Chonaill bank.
-
14th Anniversary Quests
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- Daily Quests: Finding Fruitful Fulfillment - Every day brings a different task for players to compete around the Night Bazaar for rewards. Players will be able to receive Cotton Candy from the Dessert Merchant, play in a variety of mini-games, and embark on great adventures by entering the Cave of Trials.
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- 14th Anniversary Hotdays - Players will be able to receive a special 14th Anniversary On-Time Gift Box every week and receive 10 Night Bazaar Stickers every weekend on Saturday and Sunday by logging in during the event.
- Festia Instant Prize Event - Try your luck at the Capsule Machine, located next to Fez in Festia, to open the Instant Prize window with 20,000 gold or one Instant Prize Ticket, which can be gained by participating in certain 14th Anniversary events.
On the heels of the 14th anniversary celebratory activities, players should expect Mabinogi servers to fully integrate on April 14. A new server, Erinn, will be launched on this date. It’s an exciting time to join the world of Mabinogi!
For more information on Mabinogi’s 14th anniversary and server merge, visit the official website and follow @mabinogi on Facebook for the latest updates.
Assets: Anniversary image | Server Merge image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005803/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom